HomeAboutLearnContact

How is Flarin different?

Flarin Lipid Lock® Technology

Infirst Ltd have developed a manufacturing process, for Flarin, which locks the pain reliving power of ibuprofen in a unique lipid formulation.

Flarin’s patented Lipid Lock® technology encases ibuprofen in lipids (Glycerol Monolinoleate and hard fat which are long chain fatty acids from a vegetable source) through a complex manufacturing process involving heating and dissolving specific pharmaceutical grade lipids, ibuprofen and other excipients together over several days.

Flarin is the first and only ibuprofen product with this Lipid Lock® formulation.

A double-blind, randomised, multi-centre clinical trial of episodic knee pain (FLARE study), published in Osteoarthritis and Cartilage ), showed combining ibuprofen in a lipid formulation (Flarin 200 mg soft capsules ,1200 mg/day) delivered effective relief of knee pain.

Flarin lipid formulated ibuprofen (1200mg/day) has been shown to be as effective as twice the dose (2400mg/day) of standard ibuprofen.

No other ibuprofen has been proven to be more effective for joint pain

Flarin is absorbed in the small intestine

Philip Conaghan, Professor of Musculoskeletal Medicine, commented “We now have good clinical evidence to show that combining ibuprofen in a lipid formulation can provide effective flare up control”. The FLARE study also showed evidence of fewer incidences of GI drug-related adverse events than prescription strength ibuprofen (2400 mg / day).1

  1. Bierma ‐Zeinstra SMA, Conaghan PG, Brew J et al. Osteoarthr Cartil: 2017 25; 12: 1942–1951 Open Access: http://dx.doi.org/10.1016/j.joca.2017.09.002

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to infirst Medical Information via email [email protected] or Tel: +44 (0)808 281 0143